Actively Recruiting
Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication
Led by Nova Scotia Health Authority · Updated on 2026-02-17
84
Participants Needed
1
Research Sites
91 weeks
Total Duration
On this page
Sponsors
N
Nova Scotia Health Authority
Lead Sponsor
H
Heart and Stroke Foundation of Canada
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is testing two different ways of treating atrial fibrillation (AF) in people who also have heart failure with mildly reduced or preserved heart function. Patients will randomly be assigned to either rhythm control using catheter ablation or rate control using medicines. The pilot phase will determine if a larger study can be successfully carried out to see which approach better improves survival, reduces hospitalizations, and enhances quality of life.
CONDITIONS
Official Title
Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 6518 years
- Diagnosis of atrial fibrillation documented on Holter, rhythm strip, or ECG
- New York Heart Association (NYHA) class II-III heart failure
- Left ventricular ejection fraction (LVEF) >40%
- NT-proBNP criteria met: if hospitalization for heart failure within 6 months prior to screening, NT-proBNP >200 pg/ml if not in AF at screening or >600 pg/ml if in AF at screening; otherwise, NT-proBNP >300 pg/ml if not in AF at screening or >900 pg/ml if in AF at screening
- On stable guideline-directed medical therapy for at least 1 month
- On stable diuretic dose for at least 2 weeks
- Suitable for either ablation-based rhythm control or rate control strategy
You will not qualify if you...
- Permanent atrial fibrillation diagnosis
- Prior catheter ablation for atrial fibrillation
- New York Heart Association (NYHA) class IV heart failure
- Rheumatic heart disease
- Moderate or severe mitral stenosis
- Mechanical mitral valve
- Severe aortic stenosis or severe aortic/mitral regurgitation
- Renal failure requiring dialysis
- Contraindication to oral anticoagulation
- Infiltrative cardiomyopathies
- Complex congenital heart disease
- Untreated thyroid disease
- Acute coronary syndrome or coronary artery bypass surgery within 12 weeks
- Participation in another clinical trial
- Inability to provide informed consent
- Other serious non-cardiovascular condition with life expectancy of 1 year or less
- Age under 18 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
QEII HSC
Halifax, Nova Scotia, Canada, B3H 3A7
Actively Recruiting
Research Team
L
Laura Hamilton, BSC, MAHSR
CONTACT
K
Katie Kawulka, BScN, RN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here